Connect Biopharma Holdings Limited Ordinary Shares (CNTB)

Connect Biopharma will present two poster presentations at the ERS Congress 2025 about rademikibart, a monoclonal antibody targeting IL-4Rα for treating asthma and inflammatory diseases.

Connect Biopharma reported a significant revenue drop from $24.1 million to $48,000 in Q2 2025, increased R&D expenses, and a net loss of $12.9 million. The company continues developing rademikibart for inflammatory diseases and is progressing clinical trials.

Here is how Bausch Health (BHC) and Connect Biopharma Holdings Limited Sponsored ADR (CNTB) have performed compared to their sector so far this year.

Shares of Icosavax, Inc. (NASDAQ: ICVX) rose sharply in pre-market trading after AstraZeneca announced plans to buy Icosavax in a deal valued at up to $1.1 billion. Icosavax also reported topline interim Phase 2 results for combination VLP vaccine candidate IVX-A12 against RSV and hMPV in older adults. Icosavax shares gained 44.8% to $15.19 in pre-market trading. Here are some other stocks moving in pre-market trading. Gainers Bruush Oral Care Inc. (NASDAQ: BRSH) shares rose 76.8% to $0.2882 in pre-market trading after gaining over 5% on Monday. Connect Biopharma Holdings Limited (NASDAQ: CNTB) rose 32.2% to $1.19 in pre-market trading. Connect Biopharma will present top-line data from the global Phase 2b trial evaluating rademikibart’s efficacy and safety in patients with moderate-to-severe asthma on Dec. 12, 2023. Kaival Brands Innovations Group, Inc. (NASDAQ: KAVL) shares rose 28% to $0.3159 in pre-market trading. Kaival Brands recently appointed James W. Dobbins as General Counsel. IN8bio, Inc.(NASDAQ: INAB) gained ...

Use these tips to develop a penny stocks risk management strategy The post How to Develop a Penny Stocks Risk Management Strategy appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.